Search

Displaying results 7781 - 7790 of 7901 in total
  1. Drug

    Decyl(dimethyl)phosphine oxide

    go.drugbank.com/drugs/DB07641
    Experimental

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Hymecromone

    go.drugbank.com/drugs/DB07118
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Gallium citrate

    go.drugbank.com/drugs/DB17893
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Quinoline

    go.drugbank.com/drugs/DB18050
    Investigational

    Synonyms: Benzo(b)pyridineCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.

  6. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  7. Drug

    Daxdilimab

    go.drugbank.com/drugs/DB16391
    Investigational

    Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).

  8. Drug

    Vafidemstat

    go.drugbank.com/drugs/DB16446
    Investigational

    Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).

  9. Drug

    Ezurpimtrostat

    go.drugbank.com/drugs/DB16458
    Investigational

  10. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants